Genocea Biosciences Inc GNCA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 09/24/21 EDT
2.09UNCH (UNCH)
Volume
126,692
52 week range
1.65 - 4.04
Loading...
  • Open2.09
  • Day High2.16
  • Day Low2.07
  • Prev Close2.09
  • 52 Week High4.04
  • 52 Week High Date02/16/21
  • 52 Week Low1.65
  • 52 Week Low Date08/17/21

Key Stats

  • Market Cap119.17M
  • Shares Out57.02M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.54
  • YTD % Change-13.64

KEY STATS

  • Open2.09
  • Day High2.16
  • Day Low2.07
  • Prev Close2.09
  • 52 Week High4.04
  • 52 Week High Date02/16/21
  • 52 Week Low1.65
  • 52 Week Low Date08/17/21
  • Market Cap119.17M
  • Shares Out57.02M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.54
  • YTD % Change-13.64

RATIOS/PROFITABILITY

  • EPS (TTM)-0.61
  • P/E (TTM)-3.43
  • Fwd P/E (NTM)-2.80
  • EBITDA (MRQ)-48.087M
  • ROE (MRQ)-629.16%
  • Revenue (MRQ)450,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-7,910.38%
  • Debt To Equity (MRQ)295.81%

EVENTS

  • Earnings Date10/27/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Genocea Biosciences Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Genocea Biosciences, Inc. is a biopharmaceutical company developing personalized cancer immunotherapies. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Using ATLAS, the Company can improve neoantigens for inclusion in its immunotherapies and exclude inhibitory antigens that exert an immunosuppressive effect on anti-tumor immune responses. It provides GEN-009...
Kenneth Bate
Non-Executive Chairman
William Clark
President
Diantha Duvall
Chief Financial Officer
Raymond Stapleton Jr., Ph.D.
Executive Vice President
Address
100 Acorn Park Dr
Cambridge, MA
02140-2303
United States

Top Peers

SYMBOLLASTCHG%CHG
LYRA
Lyra Therapeutics Inc
9.31+0.32+3.50%
CAPR
Capricor Therapeutics Inc
5.23+0.21+4.18%
APRE
Aprea Therapeutics Inc
4.54+0.01+0.22%
ALRN
Aileron Therapeutics Inc
1.10+0.02+1.85%
PTN
Palatin Technologies Inc
0.4566-0.0058-1.2543%